1. Home
  2. ALLK vs RMI Comparison

ALLK vs RMI Comparison

Compare ALLK & RMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLK
  • RMI
  • Stock Information
  • Founded
  • ALLK 2012
  • RMI 2018
  • Country
  • ALLK United States
  • RMI United States
  • Employees
  • ALLK N/A
  • RMI N/A
  • Industry
  • ALLK Biotechnology: Pharmaceutical Preparations
  • RMI Finance/Investors Services
  • Sector
  • ALLK Health Care
  • RMI Finance
  • Exchange
  • ALLK Nasdaq
  • RMI Nasdaq
  • Market Cap
  • ALLK 22.5M
  • RMI 95.7M
  • IPO Year
  • ALLK 2018
  • RMI N/A
  • Fundamental
  • Price
  • ALLK $0.25
  • RMI $15.74
  • Analyst Decision
  • ALLK Hold
  • RMI
  • Analyst Count
  • ALLK 3
  • RMI 0
  • Target Price
  • ALLK $2.00
  • RMI N/A
  • AVG Volume (30 Days)
  • ALLK 4.8M
  • RMI 17.4K
  • Earning Date
  • ALLK 03-13-2025
  • RMI 01-01-0001
  • Dividend Yield
  • ALLK N/A
  • RMI 7.28%
  • EPS Growth
  • ALLK N/A
  • RMI N/A
  • EPS
  • ALLK N/A
  • RMI N/A
  • Revenue
  • ALLK N/A
  • RMI N/A
  • Revenue This Year
  • ALLK N/A
  • RMI N/A
  • Revenue Next Year
  • ALLK N/A
  • RMI N/A
  • P/E Ratio
  • ALLK N/A
  • RMI N/A
  • Revenue Growth
  • ALLK N/A
  • RMI N/A
  • 52 Week Low
  • ALLK $0.23
  • RMI $13.05
  • 52 Week High
  • ALLK $1.69
  • RMI $17.37
  • Technical
  • Relative Strength Index (RSI)
  • ALLK 28.77
  • RMI 60.73
  • Support Level
  • ALLK $0.23
  • RMI $15.41
  • Resistance Level
  • ALLK $0.26
  • RMI $15.83
  • Average True Range (ATR)
  • ALLK 0.11
  • RMI 0.14
  • MACD
  • ALLK -0.08
  • RMI 0.04
  • Stochastic Oscillator
  • ALLK 1.62
  • RMI 73.47

About ALLK Allakos Inc.

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

About RMI RiverNorth Opportunistic Municipal Income Fund Inc.

RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.

Share on Social Networks: